Thousands of people with a severe dust mite allergy could benefit from a life-changing first-of-its-kind tablet on the NHS.
THOUSANDS of Brits plagued by constant sneezing, a streaming nose and red, watery eyes could be given a ‘life-changing’ pill on the NHS. The National Institute for Healthcare and Care ...
Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...
People in England with a severe dust mite allergy are set to be offered a daily pill on the NHS, it has been announced today (Thursday January 30), as part of a big shake up.
The NHS will now offer immunotherapy pill Acarizax so the body can become less sensitive to dust mites over time and halt ...
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...
EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...
GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...
GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...
Nasal steroids provided the most significant benefit, especially when compared to montelukast. Nasal antihistamines also ...